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sTo the Editor: Antineoplastic agents of the anthracycline (ANT)
group are commonly and effectively used in various forms of
malignancies. Anthracyclines might lead to irreversible cardiomy-
opathy (CMP), despite their beneficial effects. A number of
mechanisms, such as elevation in free superoxide anion radicals,
apoptosis, and mitochondrial dysfunction have been implicated in
ANT-induced CMP. However, oxidative stress has been widely
considered as the major pathogenetic mechanism (1). Statins have
been shown to possess antioxidative, pleiotropic effects (2) besides
their anti-inflammatory and lipid-lowering effects, which led us to
conduct the present study to test the potential role of statin in
ANT-induced CMP prophylaxis.
In the present study, a total of 40 patients (17 men) with a
mean age of 53  15 years who were undergoing ANT
chemotherapy were enrolled. The patients were randomized
into statin group or control group (n  20 in each group). The
patients who had a history of chemotherapy or radiotherapy,
with symptoms of heart failure or left ventricular (LV) dysfunc-
tion at baseline echocardiography, who had a history of CAD,
or with moderate-to-severe valve disease were excluded. None
of the patients were under medication that could affect cardiac
functions. The statin group received administration of 40
mg/day atorvastatin before chemotherapy, regardless of their
baseline lipid values, and the therapy continued for 6 months.
All patients received chemotherapy 1/month with either adria-
mycin or idarubicin for a period of 6 months. The primary
endpoint was the establishment of impairment in LV systolic
functions defined as an ejection fraction (EF) of 50%. All
patients were evaluated by echocardiography before and 6
months after chemotherapy by 2 independent, blinded cardiol-
ogists. Continuous variables were described as mean  SD and
analyzed with t test and Mann-Whitney U test when appropri-
ate. Fisher exact test was used for categoric variables. Two-
sample t test was used to compare mean changes after chemo-
therapy between 2 groups.
The statin and control groups were similar in age (53.7 
14.2 years and 52.6  17.6 years, respectively), sex (male 40%
and 45%, respectively), diagnosis (non-Hodgkin’s lymphoma
60% and 55%; multiple myeloma 10% and 20%; leukemia 30%
and 25%, respectively), and in treatment with other chemother-
apeutic agents (vincristine 90% and 95%; cyclophosphamide 80%
and 85%; methotrexate 25% and 25%; and prednisolone 60% and
55% or dexamethasone 10% and 15%, respectively). The doses of
adriamycin (261.4  61.1 mg vs. 251.1  77.2 mg) or idarubicin
(262.5  55.6 mg vs. 330.0  14.1 mg) were similar in statin and
control groups. No differences were observed between the groups in
terms of baseline glucose, lipid, high-sensitivity-C-reactive protein
levels, or renal and liver function tests.
In the statin group, a significant decrease was observed with
respect to lipid parameters, as expected. No elevation wasobserved in serum high-sensitivity C-reactive protein levels
after chemotherapy in the statin group, whereas there was a
significant increase in the control group (3.84  0.89 mg/dl vs.
5.43  1.78 mg/dl, p  0.0001).
Compared with baseline value (Table 1), on control echocardi-
ography, no difference was observed in the mean EF of the statin
group (61.3  7.9% vs. 62.6  9.3%, p  0.144). However, the
decrease in the control group was significant (62.9  7.0% vs.
55.0  9.5%, p  0.0001). Although 1 patient in the statin group
was observed with an EF below 50%, 5 patients in the control
group were observed with values below 50% (p  0.18). In the
statin group, no significant difference was observed between
baseline and follow-up values in terms of systolic (30.9  7.2 mm
vs. 29.6 6.1 mm, p 0.148) and diastolic diameters (46.5 7.2
m vs. 46.3  6.8 mm, p  0.868). However, in the control
roup, significant increases were observed in the follow-up values
f systolic (30.3  5.4 mm vs. 32.3  5.4 mm, p  0.0001) and
iastolic diameters (47.2  5.2 mm and 49.2  6.2 mm, p 
.013). Mean reduction in left ventricular ejection fraction and
ean increase in left ventricular end-diastolic diameter and left
entricular end-systolic diameter were significantly lower in the
tatin arm as compared with the control group (p  0.0001; p 
0.021; p  0.001, respectively).
The clinical use of doxorubicin and other quinone-
hydroquinone antitumor ANTs is limited by dose-related cardio-
toxicity. One-electron redox cycling of the quinone moiety has
long been known to form reactive oxygen species in excess of the
limited antioxidant defenses of cardiomyocytes, which render
cardiomyocytes to oxidant stress and death (1). Strategies have
been proposed to reduce ANT-induced cardiotoxicity, including
continuous instead of bolus infusion, liposomal ANT administra-
Comparison of Echocardiographic Parameters in theStudy Group Between Baseline and Follow-Up Valu s
Table 1
Comparison of Ec ocardiographic Parameters in the
Study Group Between Baseline and Follow-Up Values
Statin Group
(n  20)
Control Group
(n  20) p Value
LVEF (%)
Baseline 61.3 7.9 62.9 7.0
After 6 months 62.6 9.3 55.0 9.5
Mean change 1.3 3.8 7.9 8.0 0.001
LVEDD (mm)
Baseline 46.5 7.2 47.2 5.2
After 6 months 46.3 6.8 49.2 6.2
Mean change 0.15 4.0 2.0 3.3 0.021
LVESD (mm)
Baseline 30.9 7.2 30.3 5.4
After 6 months 29.6 6.1 32.3 5.4
Mean change 1.35 4.0 2.1 1.8 0.001
LVEF left ventricular ejection fraction; LVEDD left ventricular end-diastolic diameter; LVESD
left ventricular end-systolic diameter.tion, and addition of iron chelator dexrazoxane to chemotherapy
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August 23, 2011:988–92regime. Although data are inconclusive, various agents have been
experimented with to provide protection against ANT-induced
CMP both in animal models and humans (3,4).
Statins have been shown to decrease atherosclerosis-related
orbidity and mortality. It is currently accepted that statins do
xert protective cardiovascular effects not solely from their
ipid-lowering capacity. In this regard, antioxidative properties
re 1 of the main factors by which statins exert so-called
leiotropic effects. Because ANT-induced cardiotoxicity has
een shown to be sufficiently triggered by cardiac oxidative
tress and inflammation, in the present report it was hypothe-
ized that statins, by their pleiotropic effects, might prevent
NT-induced cardiotoxicity. In a unique animal model, Riad et
l. (5) have shown that pretreatment with fluvastatin attenuated
NT-induced CMP. They have demonstrated reduced oxida-
ive stress, enhanced expression of antioxidative enzyme mito-
hondrial superoxide dismutase 2, and reduced cardiac inflam-
ation shown by decreased tumor necrosis factor-alpha
xpression in fluvastatin-pretreated mice. They concluded that
his outcome resulted from antioxidant and anti-inflammatory
ffects of fluvastatin.
In the present study, although the inter-group difference on our
redefined primary endpoint of LV dysfunction did not reach
tatistical significance, we have shown that prophylactic use of
torvastatin could be effective in maintenance of LVEF in patients
reated with ANT. We proposed that this effect could be related to
leiotropic effects of statins.
The major limitations of the present study are small sample size,
ack of placebo group, and the limited measures of cardiac
ysfunction that were studied. Also, due to the short follow-up
eriod of the study, late CMP could not be assessed.
reatly hamper the apparent strength of their conclusion. Primar-Zeydin Acar, MD
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2009;69:695–9.Letters to the EditorThe Israel Screening Failure
Analyzing the Data to
Understand the Results
The recent paper by Steinvil et al. (1) raised our concern and
prompted the present considerations. The intriguing title conceals
the idea that pre-participation screening including 12-lead elec-
trocardiography is ineffective for modifying the occurrence of
sudden cardiac deaths (SCDs) in young athletes, in contrast with
previously reported Italian data (2).
The authors claim that the yearly incidence of SCDs has
emained unchanged (i.e., 2.54 to 2.66 per 100,000 persons) in the
eriods 1985 to 1996 and 1997 to 2009, despite implementation of
he screening program in Israel (1). Their conclusion was that
fforts to prevent SCDs in young athletes by the electrocardio-
raphic screening were worthless.
However, we believe that certain methodological limitations doily, both the number of cardiac events and the population of
competitive athletes at risk were only roughly estimated.
First, the number of SCDs was derived only from 2 Israel
newspapers, and not from a national prospective registry. News-
papers focus on fatalities occurring in elite/national-level profes-
sional athletes, whereas reports of SCDs in the much larger
population of adolescents/adults engaged in nonprofessional/
regional sports are usually overlooked. Moreover, an increase in the
number of sports-related fatal events in more recent years in
Western countries has been reported, a phenomenon that simply
reflects enhanced public recognition due to increased media
attention (3). This may also explain the relative lower prevalence of
fatal events reported in the past decades and confirms the unreli-
ability of estimating the time trend of SCDs in athletes based only
on media reporting.
Second, the population of competitive athletes at risk is not
known. Authors state that the number of registered competitive
athletes was 45,000 in 2009. They claim that proportion of
Israel population engaged in competitive sports remained un-
changed over time, but the actual size doubled, based not on
